The evolution of copy number variations in the AT-rich Plasmodium genome

富含 AT 的疟原虫基因组中拷贝数变异的进化

基本信息

  • 批准号:
    10608156
  • 负责人:
  • 金额:
    $ 40.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Changes in the copy number of large genomic regions, termed copy number variations or CNVs, contribute to phenotypic diversity and facilitate important processes such as host range and drug resistance. Despite decades of CNV research, many questions regarding their formation and dynamics remain unanswered. Due to distinctive genome characteristics, facile in vitro propagation, and the relative simplicity of CNV formation, Plasmodium falciparum is an exceptional model to study many aspects of CNV-based adaptation. Experimental evolution demonstrates how this haploid asexual parasite rapidly acquires CNVs in the form of tandem duplications. By studying the junctions of these CNVs, we have identified the precise genome characteristics that contribute to their formation in this organism; A/T-rich features of the genome both trigger DNA breakage and facilitate subsequent error-prone repair. Based on this finding, we hypothesize that the extreme AT content of the P. falciparum genome (>80%) specifically contributes to its highly adaptive nature. We aim to explore this hypothesis using different human-infective Plasmodium species, which have genomes exhibiting a range of AT- content (differing by >20% overall and ~30% in intergenic regions). To do so, we will generate highly accurate genome assemblies to characterize CNV junctions and the sequences that lead to their formation. We will identify genome features that contribute to DNA breakage and CNV formation in vivo. We will measure the frequency of novel CNV generation, under both basal and stressed conditions. These proposed studies will facilitate our creation of a genomic map of adaptive potential for different malaria species, provide firm evidence for our model of CNV formation, and define constraints influencing CNV evolution. This knowledge, and the novel methods developed during this project, will pave the way to developing approaches to limit CNV-based adaptation in diverse microorganisms, cancers, and other cell types under rapid evolution.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jennifer Lynn Guler其他文献

Jennifer Lynn Guler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jennifer Lynn Guler', 18)}}的其他基金

The evolution of copy number variations in the AT-rich Plasmodium genome
富含 AT 的疟原虫基因组中拷贝数变异的进化
  • 批准号:
    10379458
  • 财政年份:
    2021
  • 资助金额:
    $ 40.08万
  • 项目类别:
Tackling Malaria Resistance with an Integrated Modeling/Experimental Approach
通过综合建模/实验方法应对疟疾耐药性
  • 批准号:
    9111465
  • 财政年份:
    2016
  • 资助金额:
    $ 40.08万
  • 项目类别:

相似海外基金

Developing inhibitors of Plasmodium Acetyl CoA Synthetase as new multistage antimalarials
开发疟原虫乙酰辅酶A合成酶抑制剂作为新型多级抗疟药
  • 批准号:
    MR/X030202/1
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Research Grant
Novel Dual-Stage Antimalarials: Machine learning prediction, validation and evolution
新型双阶段抗疟药:机器学习预测、验证和进化
  • 批准号:
    10742205
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
Natural Product Inspired Novel Antimalarials with Radical Cure Potential
受天然产物启发的具有根治潜力的新型抗疟药
  • 批准号:
    10635649
  • 财政年份:
    2023
  • 资助金额:
    $ 40.08万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10534667
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
Plasmodium Protein Kinase Focused Antimalarials Discovery
疟原虫蛋白激酶聚焦抗疟药的发现
  • 批准号:
    10533634
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
Development of new lead antimalarials targeting parasite coenzyme A biosynthesis and utilisation.
开发针对寄生虫辅酶 A 生物合成和利用的新型先导抗疟药。
  • 批准号:
    468862
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Operating Grants
DMPK Optimisation of B-hydroxyethylamine Antimalarials
B-羟乙胺抗疟药的 DMPK 优化
  • 批准号:
    2749037
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
    Studentship
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
  • 批准号:
    10646331
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
Novel Synergistic Antimalarials with Resistance Reversal Function
具有耐药逆转功能的新型协同抗疟药
  • 批准号:
    10368441
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
Repurposing antimalarials for the treatment of NTM infections
重新利用抗疟药治疗 NTM 感染
  • 批准号:
    10494711
  • 财政年份:
    2022
  • 资助金额:
    $ 40.08万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了